He Yan, Guo Tao, Guan Hui, Wang Jingjing, Sun Yu, Peng Xingchen
Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu, Sichuan, China.
Cancer Manag Res. 2018 Jun 6;10:1419-1428. doi: 10.2147/CMAR.S160469. eCollection 2018.
In this study, we attempted to compare the efficacy and toxicity of concurrent chemoradiotherapy (CCRT) with radiotherapy alone (RT) for locoregionally advanced nasopharyngeal carcinoma (LANPC) in the era of intensity-modulated radiotherapy (IMRT) by meta-analysis.
We searched databases, and all randomized controlled trials meeting the inclusion criteria were utilized for a meta-analysis with RevMan 5.3 based on the Cochrane methodology.
Fifteen studies were found suitable based on the inclusion criteria. CCRT not only significantly improved the overall response rate (risk ratio [RR]=0.53, 95% CI 0.43-0.66) and the complete response rate (RR=0.60, 95% CI 0.51-0.71) but also contributed to longer overall survival. The incidence of grade 3-4 adverse events from CCRT group increased in hematologic toxicity (RR 2.25, 95% CI 1.54-3.29), radiation-induced oral mucositis (RR 1.64, 95% CI 1.14-2.35), and radiodermatitis (RR 1.80, 95% CI 1.13-2.88).
Compared with IMRT alone, CCRT provided survival benefit with acceptable toxicity in patients with LANPC. However, we need multicenter randomized controlled trials and long-term follow-up to evaluate the eventual efficacy and toxicity of concurrent chemotherapy plus IMRT.
在本研究中,我们试图通过荟萃分析比较调强放疗(IMRT)时代同步放化疗(CCRT)与单纯放疗(RT)治疗局部晚期鼻咽癌(LANPC)的疗效和毒性。
我们检索了数据库,并根据Cochrane方法,使用RevMan 5.3对所有符合纳入标准的随机对照试验进行荟萃分析。
根据纳入标准,发现15项研究合适。CCRT不仅显著提高了总缓解率(风险比[RR]=0.53,95%CI 0.43 - 0.66)和完全缓解率(RR=0.60,95%CI 0.51 - 0.71),还有助于延长总生存期。CCRT组3 - 4级不良事件的发生率在血液学毒性(RR 2.25,95%CI 1.54 - 3.29)、放射性口腔黏膜炎(RR 1.64,95%CI 1.14 - 2.35)和放射性皮炎(RR 1.80,95%CI 1.13 - 2.88)方面有所增加。
与单纯IMRT相比,CCRT为LANPC患者提供了生存获益且毒性可接受。然而,我们需要多中心随机对照试验和长期随访来评估同步化疗联合IMRT的最终疗效和毒性。